Trial Profile
(OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms OSKIRA-2
- Sponsors AstraZeneca
- 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 04 Jun 2013 Primary endpoint 'American-College-of-Rheumatology-20%-response-criteria significantly greater in fostamatinib + DMARDS treatment groups vs DMARDs' has been met, according to results presented in an Astra Zeneca media release.
- 04 Jun 2013 Top-line results published in a Rigel Pharmaceuticals media release.